. While little science exists supporting medical efficacy of CBD (with the exception of seizures, which GWPharma was able to prove with Epidiolex for Dravet syndrome and Lennox-Gastaut syndrome, as discussed in more detail herein), the popularity of CBD products seems to be growing exponentially in the U.

ex (highly potent, pure formulation of CBD) was approved by the FDA in 2018 for the treatment of seizures associated with Lennox-Gastaut syndrome and Dravet syndrome, and other companies (Tilray, MMJ Phytotech, Insys) have clinical trials underway in seizure disorders as well. CBD Hemp Cultivation (Neive

dermal CBD gel ZYNOO2 in Fragile X syndrome. GW conducted a broad Phase III program for Epidiolex in epilepsy, consisting of two Phase Ill trials in Dravet, two Phase II/ trials in Lennox-Gastaut syndrome (LGS), a Phase Ill trial in tuberous sclerosis complex, and a Phase II/III trial in infantile spasms